Hantz Financial Services’s Vanda Pharmaceuticals VNDA Stock Holding History

Hantz Financial Services’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,500	Closed	-$6K	–	1272
2024 Q1	$6K	Hold	1,500	–	–	﹤0.01%	914
2023 Q4	$6K	Hold	1,500	–	–	﹤0.01%	894
2023 Q3	$6K	Hold	1,500	–	–	﹤0.01%	884
2023 Q2	$10K	Hold	1,500	–	–	﹤0.01%	784
2023 Q1	$10K	Hold	1,500	–	–	﹤0.01%	788
2022 Q4	$11K	Hold	1,500	–	–	﹤0.01%	743
2022 Q3	$15K	Hold	1,500	–	–	﹤0.01%	698
2022 Q2	$16K	Hold	1,500	–	–	﹤0.01%	686
2022 Q1	$17K	Buy	+1,500	New	+$19.7K	﹤0.01%	709

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hantz Financial Services's VNDA Position: Q2 2024 in Review

Hantz Financial Services sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 1,500 shares — an estimated $6K sold.

Hantz Financial Services first reported a position in VNDA in Q1 2022 and held it in 9 quarters. The position peaked at $17K in Q1 2022. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

Hantz Financial Services reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Hantz Financial Services sold 1,500 Vanda Pharmaceuticals shares in Q2 2024, an estimated $6K.
Hantz Financial Services first reported a position in Vanda Pharmaceuticals in Q1 2022 and held it in 9 quarters.
Hantz Financial Services's Vanda Pharmaceuticals position peaked at $17K in Q1 2022.
148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Hantz Financial Services's 13F filing for Q2 2024, filed 30 Jul 2024.